Q4 Earnings Forecast for Arvinas Issued By Leerink Partnrs

Arvinas, Inc. (NASDAQ:ARVN) – Stock analysts at Leerink Partnrs issued their Q4 2025 earnings per share estimates for shares of Arvinas in a research note issued to investors on Wednesday, February 5th. Leerink Partnrs analyst A. Berens forecasts that the company will post earnings per share of ($0.93) for the quarter. The consensus estimate for Arvinas’ current full-year earnings is ($3.22) per share. Leerink Partnrs also issued estimates for Arvinas’ FY2027 earnings at $1.05 EPS.

ARVN has been the subject of several other research reports. Guggenheim reaffirmed a “buy” rating on shares of Arvinas in a research report on Thursday, December 12th. BMO Capital Markets reduced their price target on shares of Arvinas from $90.00 to $88.00 and set an “outperform” rating on the stock in a research report on Wednesday, November 20th. Barclays lowered their price objective on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating for the company in a research report on Monday. Stephens assumed coverage on Arvinas in a report on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. Finally, HC Wainwright reissued a “buy” rating and set a $87.00 price target on shares of Arvinas in a report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $61.45.

Arvinas Trading Down 2.5 %

NASDAQ:ARVN opened at $19.10 on Friday. Arvinas has a fifty-two week low of $16.61 and a fifty-two week high of $53.08. The stock has a fifty day moving average price of $19.75 and a 200-day moving average price of $23.67.

Institutional Investors Weigh In On Arvinas

A number of institutional investors and hedge funds have recently bought and sold shares of ARVN. nVerses Capital LLC bought a new position in Arvinas in the 3rd quarter valued at $39,000. KBC Group NV boosted its holdings in shares of Arvinas by 77.0% in the 4th quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after purchasing an additional 1,255 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its position in Arvinas by 21.5% in the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after buying an additional 440 shares during the last quarter. Quantbot Technologies LP boosted its stake in Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after buying an additional 2,601 shares in the last quarter. Finally, Exchange Traded Concepts LLC grew its position in Arvinas by 37.0% during the third quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock valued at $164,000 after acquiring an additional 1,798 shares during the last quarter. 95.19% of the stock is owned by hedge funds and other institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.